These therapies target either Cluster of Differentiation 19 (CD19) in BCL and B-cell precursor ALL, or B-cell maturation antigen (BCMA) in multiple myeloma (MM). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.